Clinical trial tech outfit Medidata is expanding its work in risk-based monitoring, buying a startup called Patient Profiles to help sponsors and CROs use real-time safety data to make decisions on studies.
Medidata and partner TransCelerate BioPharma, a nonprofit run by the world's largest drugmakers, are amplifying their call for clinical trial runners to embrace new technology, unveiling study results that support the adoption of risk-based monitoring.
GlaxoSmithKline and Medidata have moved mHealth tools one step closer to the clinical trial mainstream. Having run a pilot project, the partners have concluded that mHealth technologies can deliver reliable, FDA-compliant data and improve the clinical trial experience for patients.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
Medidata has promised to review its financial controls after fraudsters made away with $4.8 million. Midlevel employees in the eClinical company's finance department reportedly made the transfer to an overseas bank account after receiving a request for $4.8 million.
CRO magnate Icon and and eClinical outfit Medidata are pooling their resources to offer a combined platform for patient-reported outcomes in clinical trials, touting their technology as faster and more effective in surveying participants.
Medidata is providing the underlying technology, while Icon is contributing its pre-validated surveys.
With some biopharma still wary of moving their data into the cloud and the rest seeking vendors with solid cybersecurity credentials, Medidata has tapped Sumo Logic and The Herjavec Group (THG) to bolster its defenses. The new system uses machine-learning algorithms to identify threats.
Cloud-based data magnate Medidata has signed a deal with TransCelerate BioPharma, a consortium of the world's largest drugmakers, to modernize the way the industry conducts clinical trials.
The potential cost savings generated by risk-based monitoring of clinical trials has led some to tip it as a way to significantly streamline pharma's flabby studies. And that potential has lured tech providers, with Medidata and Parexel both advancing their claims on the market this week.